ANTIBODIES TO NTB-A

• US 20110171204A1
• Filed: 12/07/2010
• Published: 07/14/2011
• Est. Priority Date: 08/28/2006
• Status: Active Grant

• Current Assignee: Arca Biopharma, Inc.
• Original Assignee: Arca Biopharma, Inc.
• Inventors: Abo, Arie, Korver, Wouter
• Granted Patent: US 8,193,320 B2
• Time in Patent Office: Days
• US Class Current: 424/130.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 2039/507 Comprising a combination of two or more separate antibodies
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: C07K 16/28 against receptors, cell surface antigens or cell surface determinants
• CPC Class Codes: C07K 16/2803 against the immunoglobulin superfamily
• CPC Class Codes: C07K 2299/00 Coordinates from 3D structures of peptides, e.g. proteins or enzymes
• CPC Class Codes: C07K 2317/14 Specific host cells or culture conditions, e.g. components, pH or temperature
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/565 Complementarity determining region [CDR]
• CPC Class Codes: C07K 2317/732 Antibody-dependent cellular cytotoxicity [ADCC]
• CPC Class Codes: C07K 2317/734 Complement-dependent cytotoxicity [CDC]
• CPC Class Codes: C07K 2317/92 Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
• CPC Class Codes: G01N 33/57426 leukemia

Abstract

Anti-NTB-A antibodies and antigen-binding fragments thereof, as well as pharmaceutical compositions comprising such antibodies and antigen-binding fragments are described. Also described are methods of using such antibodies and antigen-binding regions to bind NTB-A and treat diseases, such as hematologic malignancies, which are characterized by expression of NIB-A.

Claims

1. An isolated antibody or antigen-binding fragment thereof, comprising:

a) a heavy chain, comprising a first variable region, comprising an amino acid sequence that has at least 90% identity to SEQ ID NO;

5 or 9; and

b) a light chain comprising a second variable region, comprising an amino acid sequence that has at least 90% identity to SEQ ID NO;

7 or 11.

5. The antibody of claim 1, wherein the heavy chain and the light chain are connected by a flexible linker to form a single chain antibody.

11. The antibody of claim 1, which is humanized.

12. The antibody of claim 1, which is chimeric.

13. A nucleic acid molecule encoding the antibody of claim 1.

17. A host cell transformed with the nucleic acid of claim 13.

21. A pharmaceutical composition comprising an antibody of claim 1, further comprising a suitable carrier.

25. A method of detecting the level of NTB-A in a biological sample, comprising contacting the sample with the antibody or antigen-binding fragment of claim 1.

71. The antibody of claim 1, wherein said antibody is murine anti-NTB-A monoclonal antibody 480.12 comprising an amino acid sequence of the monoclonal antibody produced by a hybridoma having ATCC Deposit No. PTA-7832, or progeny thereof.

72. The antibody of claim 71, wherein said antibody is a humanized or chimeric form thereof.

2-4. -4. (canceled)

6-10. -10. (canceled)

14-16. -16. (canceled)

18-20. -20. (canceled)

22-24. -24. (canceled)

26. A selective binding agent comprising any of SEQ ID NO:

24, 27, 30, or 33.

35. The selective binding agent of claim 26, wherein the heavy chain and the light chain are connected by a flexible linker to form a single chain antibody.

41. The selective binding agent of claim 26, which is humanized.

42. The selective binding agent of claim 26, which is chimeric.

43. A pharmaceutical composition comprising the selective binding agent of claim 26, further comprising a suitable carrier.

27-31. -31. (canceled)

33-34. -34. (canceled)

36-40. -40. (canceled)

44-59. -59. (canceled)

61-70. -70. (canceled)

73-74. -74. (canceled)